Guangdong Lung Cancer Institute

Guangzhou, China

Guangdong Lung Cancer Institute

Guangzhou, China
SEARCH FILTERS
Time filter
Source Type

News Article | May 19, 2017
Site: www.eurekalert.org

"This study identifies a subset of patients with lung cancer who can benefit from a targeted treatment that causes far fewer side effects than chemotherapy," said ASCO President-Elect Bruce E. Johnson, MD, FASCO. "It's also clear evidence that we can use precision medicine not only in patients with advanced cancer, but also in those with earlier stage disease." ALEXANDRIA, Va. - The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) who received gefitinib went about 10 months longer without recurrence than patients who received chemotherapy. The study will be presented at the upcoming 2017 ASCO Annual Meeting in Chicago. "Adjuvant gefitinib may ultimately be considered as an important option for stage II-IIIA lung cancer patients with an active EGFR mutation, and we may consider routine EGFR testing in this earlier stage of lung cancer," said lead study author Yi-Long Wu, MD, a director of the Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China. "We intend to follow these patients until we can fully measure overall survival as opposed to disease-free survival, which just measures disease recurrence." Due to high chance of recurrence, the five-year survival for patients with stage II-IIIA NSCLC is only 40%. About 25% of all patients who are diagnosed with NSCLC are eligible to have surgery to remove the tumors with the hope of a cure. Among that group, about 30% or 140,000 people worldwide have an EGFR mutation in the tumor and may benefit from adjuvant treatment with EGFR-targeted therapy to reduce the chance of recurrence. Following surgery, 222 patients who had confirmed activating EGFR mutations in the tumor were randomly assigned to receive gefitinib or chemotherapy (vinorelbine plus cisplatin). Patients received gefitinib daily for 24 months or the standard therapy regimen every three weeks for four cycles. According to the authors, chemotherapy was given for a shorter period of time because it is usually not tolerated well for longer periods of time. All patients were followed for disease relapse for about three years. "Two recent targeted therapy trials of adjuvant therapy did not show benefit in NSCLC, in part because they included stages I, II, and III of the disease in their design," said Dr. Wu. "The earlier trials only looked to see if patients showed overexpression, or over-activity, of EGFR, but not mutations in EGFR. Our trial recruited patients who had been confirmed to have activating EGFR mutations so we believe these reasons account for why other trials showed no benefit of a targeted therapy while ours did." Gefitinib blocks the signaling through the EGFR and is only effective in cancers with mutated and overactive EGFR. It was initially approved by the FDA in 2003 as a third-line therapy for patients with advanced NSCLC, but it is now approved as initial therapy for advanced NSCLC with an EGFR mutation. The median time to recurrence (disease-free survival) was 28.7 months for patients who received gefinitib and 18 months for those who received chemotherapy. There were 76 patient deaths (34.2% of all enrollees) during the trial period; 41 occurred in the gefinitib group and 35 in the chemotherapy group. Far fewer patients experienced severe side effects with gefitinib (12%) than with chemotherapy (48%). The most common serious side effect in the gefitinib group was elevated liver enzymes, whereas patients in the chemotherapy group had more severe quality of life concerns, including vomiting, nausea, low blood counts, and anemia. As the researchers have a tissue repository from the surgically removed lung tumors, they plan to perform a comprehensive biomarker analysis looking for other potential biomarkers for gefitinib response or resistance, in addition to EGFR. Dr. Wu stated that a fuller analysis of treatment outcomes is also planned. This study received funding from Chinese Thoracic Oncology Group (CTONG) and AstraZeneca China.


Xie Z.,Guangdong Academy of Medical science | Xie Z.,Southern Medical University | Chen G.,Guangzhou City | Zhang X.,Guangdong Lung Cancer Institute | And 5 more authors.
PLoS ONE | Year: 2013

Background and Purpose: Tissue microRNAs (miRNAs) can detect cancers and predict prognosis. Several recent studies reported that tissue, plasma, and saliva miRNAs share similar expression profiles. In this study, we investigated the discriminatory power of salivary miRNAs (including whole saliva and saliva supernatant) for detection of esophageal cancer. Materials and Methods: By Agilent microarray, six deregulated miRNAs from whole saliva samples from seven patients with esophageal cancer and three healthy controls were selected. The six selected miRNAs were subjected to validation of their expression levels by RT-qPCR using both whole saliva and saliva supernatant samples from an independent set of 39 patients with esophageal cancer and 19 healthy controls. Results: Six miRNAs (miR-10b*, miR-144, miR-21, miR-451, miR-486-5p, and miR-634) were identified as targets by Agilent microarray. After validation by RT-qPCR, miR-10b*, miR-144, and miR-451 in whole saliva and miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. Conclusions: We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk. © 2013 Xie et al.


Solomon B.J.,Peter MacCallum Cancer Center | Mok T.,Chinese University of Hong Kong | Kim D.-W.,Seoul National University | Wu Y.-L.,Guangdong Lung Cancer Institute | And 11 more authors.
New England Journal of Medicine | Year: 2014

Background The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.Methods We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up to six cycles. Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy. The primary end point was progression- free survival as assessed by independent radiologic review.Results Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001). Objective response rates were 74% and 45%, respectively (P<0.001). Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-year survival was 84% with crizotinib and 79% with chemotherapy. The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite. As compared with chemotherapy, crizotinib was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.Conclusions Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. (Funded by Pfizer; PROFILE 1014 ClinicalTrials.gov number, NCT01154140.). © 2014 Massachusetts Medical Society.


News Article | December 6, 2016
Site: www.eurekalert.org

Vienna, Austria--December 6, 2016--Today's press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on active prevention, with researchers sharing results of clinical drug trials that have shown reduction in risk of disease progression among lung cancer patients. Abstracts and full versions of news releases for each topic covered are available, including the complete article on the AURA3 Trial that is published in today's New England Journal of Medicine. Contact IASLC media representative Chris Martin at cmartin@davidjamesgroup.com for more information. Please visit http://wclc2016. to view a recording of the press briefing. Results from the AURA3 trial show osimertinib reduces risk of disease progression by 70 percent in patients with non-small cell lung cancer. Patients enrolled in the AURA3 trial who received osimertinib experienced a 70 percent reduction in progression-free disease compared to patients enrolled in a control group who only received chemotherapy. The results of the study were presented at the IASLC 17th WCLC by Dr. Vassiliki Papadimitrakopoulou, of MD Anderson Cancer Center in Houston, and were published in the New England Journal of Medicine. To read the full news release, click here: http://bit. Chinese researchers demonstrate that icotinib creates better progression-free survival with fewer side effects than whole brain radiation in non-small cell lung cancer patients with brain metastases. Patients whose lung cancer spreads to their brain typically have less than six months left to live, but research presented today suggests that using icotinib increases longevity in these patients compared to whole brain radiation and chemotherapy combined. The research was presented by Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China. For the complete news release, click here: http://bit. . Results from ASCEND-4 trial show patients receiving first-line ceritinib experienced a 45 percent risk reduction of disease progression compared to chemotherapy. Patients who received first-line ceritinib experienced a 45-percent risk reduction for advanced (ALK+) and non-small cell lung cancer compared to a control group that received chemotherapy, according to research presented by Dr. Gilberto De Castro Jr. of the Instituto do Cancer do Estado de Sao Paulo, Brazil. For the full news release, click here: http://bit. A revised tumor classification, based on more than 70,000 non-small cell lung cancer patients and 6,100 small cell lung cancer patients, is now available to lung cancer specialists around the world in the form of the 8th Edition of the Tumor, Node, and Metastasis (TNM) Classification. The new edition is published by the Union for International Cancer Control, the American Joint Committee on Cancer, and the International Association for the Study of Lung Cancer (IASLC) in their respective staging manuals. According to Dr. Ramon Rami-Porta from Hospital Universitari Mutua Terrrassa, Terrassa, Spain, the new edition seeks to improve the classification of the anatomical extent of lung cancer. To read more about the new Staging Manual, click here: http://bit. In 1998, IASLC established its Lung Cancer Staging Project, an effort to collect a significant, international database of lung cancer cases and their anatomical classifications. IASLC collected and published a large amount of data regarding the size of tumors, lymph node involvement and metastatic status which is then presented to the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) for evaluation. Before the IASLC Staging Project, data collected for staging of lung cancer came from a smaller group of patients, almost exclusively based in the U.S. The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. Organized under the theme of "Together Against Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit http://wclc2016. . The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www. for more information.


News Article | December 7, 2016
Site: www.prweb.com

ACEA Biosciences, Inc. presented today updated efficacy and safety data from its phase I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, at the World Conference on Lung Cancer (WCLC) 2016 in Vienna, Austria. The purpose of the trial was to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M‐postitive non-small cell lung cancer (NSCLC) patients after treatment with first generation EGFR tyrosine kinase inhibitors (TKIs) have failed to produce a durable response. AC0010 is an orally available, irreversible small molecule tyrosine kinase inhibitor in development for the treatment of patients with EGFRmut-positive NSCLC. It was designed specifically to inhibit epidermal growth factor receptor (EGFR) active mutations (L858R, Exon 19 del) and the T790M acquired resistance mutation. “Based on AC0010’s encouraging efficacy, tolerability, and distinct safety profile, it appears that this novel compound may provide an important treatment option for NSCLC patients who carry the EGFR T790M-positive resistance mutation,” said lead investigator of the trial Dr. Yi-Long Wu, MD, of the Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH), and Guangdong Academy of Medical Sciences in Guangzhou, China. “Based on the good efficacy and tolerability, a 300 mg BID dose was selected as the RP2D.” “About 1.8 million new patients are diagnosed with lung cancer every year and, amongst these, 15-40% develop EGFR mutations. Considering these sobering numbers, we are very pleased with the preliminary efficacy and safety data for AC0010. The results presented today make us optimistic that further clinical trials of AC0010 as a treatment option for patients with advanced NSCLC is highly justified. We have initiated two registration trials in China, as well as a multicenter open-label phase I/II trial in the USA,” said Dr. Xiao Xu, President and CEO of ACEA Biosciences. “We will continue to work closely with patients, investigators, and regulatory agencies around the world to bring this important treatment option to NSCLC patients.” In the study presented at WCLC, oral AC0010 was administered on a 28‐day cycle with a starting dose of 50 mg twice per day (BID). In any given dose regimen, if 1 out of 3 patients demonstrated a partial response within the first cycle, and no dose-limiting toxicity was determined, up to 20 patients were subsequently enrolled. Plasma samples were collected to evaluate the pharmacokinetics of AC0010, and the presence of the T790M mutation in biopsy samples was evaluated by a central laboratory. The primary efficacy outcome measures for this analysis were objective response rate (ORR) and disease control rate (DCR), as assessed by the investigator according to RECIST v.1.1. Summary of Efficacy Data Using the international rules for Response Evaluation Criteria in Solid Tumors (RECIST) responses were observed at all dose levels except 50 mg BID. Amongst 158 patients evaluated in all regimens, the ORR (including unconfirmed responses) was 42%. In the dose cohorts between 200 mg BID and 300 mg BID (n=103 pts), the ORR and DCR were 50% and 90%, respectively. At 300 mg BID, which was selected as RP2D, a total of 48 patients were treated and the ORR and DCR were 52% and 94%, respectively. Pharmacokinetic analyses demonstrate rapid absorption with a Tmax of 2­4 hours and a median T1/2 of 7-8 hours. Summary of Safety Data As of 28 Oct 2016, 158 patients have been treated across 7 drug regimens (50, 100, 150, 200, 250, 300, and 350 mg BID). At the 28 Oct 2016 cutoff, 158 patients were evaluable. Maximum Tolerated Dose (MTD) has not been reached. The most common adverse events (AE) regardless of study drug relationship were diarrhea (43%), rash (28%), and ALT/AST elevation (44%/41%). Most AEs were grade 1 and 2. The most common Grade 3/4 drug related AEs were diarrhea (1%), rash (1%), and ALT/AST elevation (5%, 3%). All patients with grade 3/4 AEs recovered after either stopping the treatment or reducing the dose. As of the cutoff date, no cases of Grade 2/3 hyperglycemia were observed, and no patients had AEs leading to death. About AC0010 AC0010 is a pyrrolopyrimidine-based irreversible inhibitor of the EGFR tyrosine kinase which is in development for the treatment of NSCLC. Structurally distinct from previously reported pyrimidine-based irreversible EGFR inhibitors such as Osimertinib, AC0010 selectively inhibits EGFR active and T790M mutations up to a 298-fold more efficiently than wild-type EGFR. Multiple clinical trials currently underway in China and the USA are demonstrating the utility of AC0010 in this patient population. ACEA holds worldwide rights for AC0010. About ACEA Biosciences ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company focused on the development and commercialization of innovative cell analysis instrumentation for life sciences, and on the discovery and development of novel pharmaceutical products for the treatment of chronic diseases. ACEA’s instruments, xCELLigence® and NovoCyte™, are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. More than 1,700 instruments have been placed globally, leading to >1,250 peer-reviewed publications from both academia and the pharmaceutical industry in diverse applications spanning everything from cancer immunotherapy and cardiotoxicity to chemotactic migration and GPCR inhibition. ACEA has leveraged its technology platform to develop a robust pipeline of clinical and preclinical small molecules for the treatment of cancer and autoimmune diseases, with two clinical stage programs running in China and the USA. ACEA Biosciences is headquartered in San Diego, California with world-class manufacturing operations in Hangzhou, China. For more information on ACEA’s ongoing clinical trials please [click here.


News Article | December 1, 2016
Site: www.prweb.com

ACEA Biosciences, Inc. announced today that it will be presenting updated efficacy and safety data from its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. “We look forward to providing an update on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M resistance mutation,” said Dr. Xiao Xu, President and CEO of ACEA. “These interim data demonstrate the promising clinical activity and tolerability profile of AC0010 in the treatment of NSCLC. The availability of alternative treatment options like AC0010 will provide patients and physicians with flexibility as they tailor treatment regimens based on efficacy and tolerability.” Presentation Detail Abstract 5117 - Phase I/II Study of AC0010, Mutant­Selective EGFR Inhibitor, in Non­Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation. Presented by: Dr. Yi-Long Wu, MD, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH), and Guangdong Academy of Medical Sciences, Guangzhou/China. About AC0010 AC0010 is an orally available, irreversible small molecule tyrosine kinase inhibitor in development for the treatment of EGFR active and T790M mutations in NSCLC patients. In preclinical studies AC0010 has been found to selectively inhibit EGFR active (Exon 19 del, L858R) and T790M mutations up to 298-fold more efficiently than wild-type EGFR. Multiple clinical trials are currently underway in China and in the USA to demonstrate the clinical utility of AC0010 in NSCLC patients who have developed the EGFR 790M mutation. AC0010 is also being developed as a first-line therapy for treatment of the EGFR activating mutations Exon 19 del and L858R. ACEA holds worldwide rights for AC0010. About ACEA Biosciences ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company focused on the development and commercialization of innovative cell analysis instrumentation for life sciences, and on the discovery and development of novel pharmaceutical products for the treatment of chronic diseases. ACEA’s instruments, xCELLigence® and NovoCyte®, are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. More than 1,700 instruments have been placed globally, leading to >1,250 peer-reviewed publications from both academia and the pharmaceutical industry in diverse applications spanning everything from cancer immunotherapy and cardiotoxicity to chemotactic migration and GPCR inhibition. ACEA has leveraged its technology platform to develop a robust pipeline of clinical and preclinical small molecules for the treatment of cancer and autoimmune diseases, with two clinical stage programs running in China and the USA. ACEA Biosciences is headquartered in San Diego, California with world-class manufacturing operations in Hangzhou, China. For more information on ACEA’s ongoing clinical trials, click here.


WIEN, ÖSTERREICH--(Marketwired - 7. Dezember 2016) - Die heutige Presseinformation zur 17. Welt-Lungenkrebs-Konferenz (World Conference on Lung Cancer, WCLC) der IASLC setzte den Akzent auf aktive Prävention. Forscher stellten Ergebnisse klinischer Studien vor, die eine Reduzierung des Risikos einer Krankheitsprogression bei Lungenkrebspatienten gezeigt haben. Es stehen Auszüge sowie vollständige Ausgaben der Pressemitteilungen zu jedem behandelten Thema zur Verfügung, darunter der ungekürzte Artikel zur Studie AURA3, der in der heutigen Ausgabe des New England Journal of Medicine erscheint. Weitere Informationen erhalten Sie von Chris Martin, Medienbeauftragter der IASLC, unter cmartin@davidjamesgroup.com. Von den Patienten, die an der Studie AURA3 teilnahmen und Osimertinib erhielten, wurde eine Reduzierung der Krankheitsprogression um 70 % im Vergleich mit Patienten einer Kontrollgruppe, die ausschließlich mit Chemotherapie behandelt wurden, festgestellt. Die Ergebnisse der Studie wurden bei der 17. Welt-Lungenkrebs-Konferenz der IASLC von Dr. Vassiliki Papadimitrakopoulou, MD Anderson Cancer Center in Houston, vorgestellt und im New England Journal of Medicine veröffentlicht. Um die vollständige Pressemitteilung zu lesen, klicken Sie bitte hier. Patienten, bei denen der Lungenkrebs auf das Gehirn übergreift, haben in der Regel weniger als sechs Monate zu leben. Die heute vorgestellten Forschungsergebnisse deuten jedoch darauf hin, dass eine Therapie mit Icotinib bei diesen Patienten im Vergleich mit Patienten, die eine Bestrahlung des gesamten Gehirns in Kombination mit Chemotherapie erhalten, die Lebensdauer verlängert. Die Untersuchung wurde von Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China, vorgestellt. Um die vollständige Pressemitteilung zu lesen, klicken Sie bitte hier. Eine revidierte Tumorklassifizierung, die auf der Behandlung von mehr als 70.000 Patienten mit nicht-kleinzelligem Lungenkarzinom sowie 6.100 Patienten mit kleinzelligem Lungenkarzinom beruht, steht nun Lungenkrebsspezialisten auf der ganzen Welt in Form der 8. Ausgabe der TNM-Klassifikation zur Stadienbestimmung bösartiger Tumore, Lymphknoten und Metastasen zur Verfügung. Die neue Ausgabe wird von der Union for International Cancer Control, dem American Joint Committee on Cancer und der International Association for the Study of Lung Cancer (IASLC) in deren jeweiligen Handbüchern zur Stadieneinteilung veröffentlicht. Laut Dr. Ramon Rami-Porta vom Hospital Universitari Mutua Terrrassa, Terrassa, Spanien, will die Neuausgabe die Klassifikation des anatomischen Ausmaßes von Lungenkrebs verbessern. Um mehr über das neue Handbuch zur Stadieneinteilung zu lesen, klicken Sie bitte hier. 1998 startete die IASLC in dem Bemühen, eine aussagekräftige, internationale Datenbank von Lungenkrebsfällen und deren anatomischen Klassifikationen einzurichten, ihr Lung Cancer Staging Project. Die IASLC sammelte und veröffentlichte umfangreiche Daten in Hinblick auf die Größe von Tumoren, Lymphknotenbeteiligung und Metastasenstatus, die im Anschluss der Union for International Cancer Control (UICC) sowie dem American Joint Committee on Cancer (AJCC) zur Auswertung vorgelegt wurden. Bevor es das IASLC Staging Project gab, wurden Daten zur Stadieneinteilung von Lungenkrebs in kleineren Patientengruppen erhoben, die fast ausnahmslos in den Vereinigten Staaten lebten.


VIENNA, AUSTRIA--(Marketwired - December 06, 2016) - Today's press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on active prevention, with researchers sharing results of clinical drug trials that have shown reduction in risk of disease progression among lung cancer patients. Abstracts and full versions of news releases for each topic covered are available, including the complete article on the AURA3 Trial that is published in today's New England Journal of Medicine. Contact IASLC media representative Chris Martin at cmartin@davidjamesgroup.com for more information. Please visit http://wclc2016.iaslc.org/live-stream/ to view a recording of the press briefing. Results from the AURA3 trial show osimertinib reduces risk of disease progression by 70 percent in patients with non-small cell lung cancer. Patients enrolled in the AURA3 trial who received osimertinib experienced a 70 percent reduction in progression-free disease compared to patients enrolled in a control group who only received chemotherapy. The results of the study were presented at the IASLC 17th WCLC by Dr. Vassiliki Papadimitrakopoulou, of MD Anderson Cancer Center in Houston, and were published in the New England Journal of Medicine. To read the full news release, click here. Chinese researchers demonstrate that icotinib creates better progression-free survival with fewer side effects than whole brain radiation in non-small cell lung cancer patients with brain metastases. Patients whose lung cancer spreads to their brain typically have less than six months left to live, but research presented today suggests that using icotinib increases longevity in these patients compared to whole brain radiation and chemotherapy combined. The research was presented by Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China. For the complete news release, click here. Results from ASCEND-4 trial show patients receiving first-line ceritinib experienced a 45 percent risk reduction of disease progression compared to chemotherapy. Patients who received first-line ceritinib experienced a 45 percent risk reduction for advanced (ALK+) and non-small cell lung cancer compared to a control group that received chemotherapy, according to research presented by Dr. Gilberto De Castro Jr. of the Instituto do Cancer do Estado de Sao Paulo, Brazil. For the full news release, click here. A revised tumor classification, based on more than 70,000 non-small cell lung cancer patients and 6,100 small cell lung cancer patients, is now available to lung cancer specialists around the world in the form of the 8th Edition of the Tumor, Node, and Metastasis (TNM) Classification. The new edition is published by the Union for International Cancer Control, the American Joint Committee on Cancer, and the International Association for the Study of Lung Cancer (IASLC) in their respective staging manuals. According to Dr. Ramon Rami-Porta from Hospital Universitari Mutua Terrrassa, Terrassa, Spain, the new edition seeks to improve the classification of the anatomical extent of lung cancer. To read more about the new Staging Manual, click here. In 1998, the IASLC established its Lung Cancer Staging Project, an effort to collect a significant, international database of lung cancer cases and their anatomical classifications. The IASLC collected and published a large amount of data regarding the size of tumors, lymph node involvement, and metastatic status which is then presented to the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) for evaluation. Before the IASLC Staging Project, data collected for staging of lung cancer came from a smaller group of patients, almost exclusively based in the U.S. The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. Organized under the theme of "Together Against Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit http://wclc2016.iaslc.org/. The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.


VIENNA, AUSTRIA--(Marketwired - 6 de dezembro de 2016) - A coletiva com a mídia de hoje na IASLC 17a Conferência Mundial sobre o Câncer de Pulmão (World Conference on Lung Cancer - WCLC) concentrou-se na prevenção ativa, com os pesquisadores compartilhando os resultados dos testes clínicos com medicamentos que demonstraram a redução do risco da progressão da doença nos pacientes com câncer de pulmão. Abstratos e versões completas dos releases de cada tópico estão disponíveis, inclusive o artigo completo sobre o Teste AURA3 publicado hoje no New England Journal of Medicine. Contate Chris Martin, representante de mídia da IASLC no cmartin@davidjamesgroup.com para mais informação. Os pacientes inscritos no teste AURA3 que receberam o osimertinib apresentaram uma redução de 70 por cento na progressão da doença, comparado com os pacientes inscritos em um grupo de controle que recebeu somente quimioterapia. O resultado da pesquisa foi apresentado na IASLC 17a WCLC pelo Dr. Vassiliki Papadimitrakopoulou, de MD Anderson Cancer Center de Houston, e publicados no New England Journal of Medicine. Para ler o release completo, clique aqui. Pesquisadores chineses demonstraram que o icotinib cria uma sobrevivência sem progressão melhor com menos efeitos colaterais do que a radiação total do cérebro de pacientes com câncer de pulmão de célula não pequena que apresentaram metástase no cérebro. Os pacientes cujo câncer de pulmão se espalha para o cérebro normalmente têm menos de seis meses de vida, mas a pesquisa apresentada hoje sugere que o uso do icotinib aumenta a longevidade nestes pacientes, comparado com a combinação da radiação total do cérebro e a quimioterapia. A pesquisa foi apresentada por Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China. Para o release completo, clique aqui. Os pacientes que receberam ceritinib de primeira linha tiveram uma redução de risco de 45 por cento no câncer de pulmão avançado (ALK+) e de célula não pequena, comparado com um grupo de controle que recebeu quimioterapia, de acordo com a pesquisa apresentada pelo Dr. Gilberto de Castro Jr. do Instituto do Câncer do Estado de São Paulo, Brasil. Para o release completo, clique aqui. Uma classificação de tumor, baseada em mais de 70.000 pacientes de câncer de pulmão de célula não pequena e 6.100 pacientes de câncer de pulmão de célula pequena, está disponível para especialistas de câncer de pulmão em todo o mundo na 8th Edition of the Tumor, Node, and Metastasis (TNM) Classification (Oitava Classificação de Tumor, Nódulos e Metástase). A nova edição é publicada pela Union for International Cancer Control, American Joint Committee on Cancer, e International Association for the Study of Lung Cancer (IASLC) nos seus respectivos manuais de estágios. De acordo com o Dr. Ramon Rami-Porta do Hospital Universitari Mutua Terrrassa, Terrassa, Espanha, a nova edição tem por objetivo melhorar a classificação da extensão anatômica do câncer de pulmão. Para ler mais sobre o Manual dos Estágios (Staging Manual), clique aqui. Em 1998, a IASLC criou o Projeto de Estágios de Câncer de Pulmão (Lung Cancer Staging Project), um esforço para coletar um banco de dados internacional significante dos casos de câncer de pulmão e suas classificações internacionais. A IASLC coletou e publicou uma vasta quantidade de dados com relação ao tamanho dos tumores, envolvimento dos linfonodos e status da metástase e enviou os dados para a Union for International Cancer Control (UICC) e para a American Joint Committee on Cancer (AJCC) para avaliação. Antes do Projeto de Estágio da IASLC, os dados coletados quanto aos estágios do câncer de pulmão tinham origem em um pequeno grupo de pacientes, quase todos exclusivamente localizados nos EUA. A WCLC é a maior conferência do mundo dedicada ao câncer de pulmão e outras doenças malignas do tórax pois atrai 6.000 pesquisadores, médicos e especialistas de mais de 100 países. O objetivo da conferência é aumentar o conhecimento, a colaboração e o entendimento do câncer de pulmão, e para ajudar os participantes a implementar os mais recentes desenvolvimentos em todo o mundo. Com o tema "Juntos contra o Câncer de Pulmão", a conferência abrangerá uma ampla variedade de disciplinas e apresentará resultados de vários estudos de pesquisa e testes clínicos. Para mais informação, visite http://wclc2016.iaslc.org/. A International Association for the Study of Lung Cancer (IASLC) é a única organização global dedicada ao estudo do câncer de pulmão. Fundada em 1974, a associação conta com mais de 5.000 especialistas em mais de 100 países. Visite www.iaslc.org para mais informação.


VIENNE, AUTRICHE--(Marketwired - 6 décembre 2016) - Le point-presse d'aujourd'hui à l'occasion de la 17e Conférence mondiale sur le cancer du poumon (WCLC) de l'IASLC s'est concentré sur la prévention active, avec des présentations par des chercheurs d'essais cliniques sur des médicaments ayant affiché une réduction du risque de progression de la maladie chez des patients atteints de cancer du poumon. Des résumés et des versions complètes de communiqués de presse pour chaque thème couvert sont disponibles, y compris l'article complet sur l'essai AURA3, qui est publié dans l'édition d'aujourd'hui du New England Journal of Medicine. Pour en savoir plus, veuillez contacter Chris Martin, représentant de l'IASLC auprès des médias, à l'adresse : cmartin@davidjamesgroup.com. Pour visualiser un enregistrement du point-presse, rendez-vous sur : http://wclc2016.iaslc.org/live-stream/. Les résultats de l'essai AURA3 montrent que l'osimertinib réduit le risque de progression de la maladie de 70 % chez les patients atteints de cancer du poumon non à petites cellules. Chez les patients recrutés dans l'essai AURA3 ayant reçu de l'osimertinib, une réduction de 70 % de la survie sans progression a été enregistrée, comparativement aux patients recrutés dans un groupe-témoin ayant subi uniquement une chimiothérapie. Les résultats de l'étude ont été présentés à l'occasion de la 17e WCLC de l'IASLC par le Dr Vassiliki Papadimitrakopoulou du MD Anderson Cancer Center à Houston, et ont été publiés dans le New England Journal of Medicine. Pour consulter le communiqué de presse dans son intégralité, cliquez ici. Des chercheurs chinois démontrent que l'icotinib génère une meilleure survie sans progression avec moins d'effets secondaires qu'une radiothérapie encéphalique, chez des patients atteints de cancer du poumon non à petites cellules avec des métastases cérébrales. Les patients dont le cancer du poumon se propage jusqu'à leur cerveau ont généralement moins de six mois à vivre, mais l'étude présentée aujourd'hui suggère que l'utilisation de l'icotinib augmente la longévité de ces patients, comparativement à la combinaison de chimiothérapie et de radiothérapie encéphalique. Cette étude a été présentée par Yi-long Wu du Guangdong Lung Cancer Institute de l'Hôpital général de Guangdong et de l'Académie des sciences médicales de Guangdong, en Chine. Pour consulter le communiqué de presse dans son intégralité, cliquez ici. Les résultats de l'essai ASCEND-4 montrent que les patients recevant du ceritinib en tant que traitement de première intention ont affiché une réduction du risque de progression de la maladie de 45 % par rapport à la chimiothérapie. D'après cette étude présentée par le Dr Gilberto De Castro Jr. de l'Instituto do Cancer do Estado de Sao Paulo, au Brésil, chez les patients ayant reçu du ceritinib en tant que traitement de première intention, on a enregistré une réduction de 45 % du risque pour le cancer du poumon à un stade avancé (ALK+) et non à petites cellules, comparativement à un groupe-témoin ayant reçu une chimiothérapie. Pour consulter le communiqué de presse dans son intégralité, cliquez ici. Un nouveau manuel d'identification des tumeurs de cancer du poumon vise à façonner le traitement clinique du cancer du poumon. Une classification révisée des tumeurs, basée sur plus de 6 100 patients atteints de cancer du poumon non à petites cellules, est désormais disponible pour les spécialistes du cancer du poumon du monde entier sous la forme de la 8e édition de la Classification des tumeurs, ganglions lymphatiques et métastases (TNM pour Tumor, Node et Metastasis). Cette nouvelle édition est publiée par l'Union for International Cancer Control, l'American Joint Committee on Cancer et l'International Association for the Study of Lung Cancer (IASLC) dans leurs manuels d'identification respectifs. D'après le Dr Ramon Rami-Porta de l'Hospital Universitari Mutua Terrrassa, à Terrassa (Espagne), cette nouvelle édition vise à améliorer la classification de l'étendue anatomique du cancer du poumon. Pour en savoir plus sur le nouveau Manuel d'identification, cliquez ici. En 1998, l'IASLC a établi son Lung Cancer Staging Project, un effort visant à constituer une base de données internationale significative de cas de cancer du poumon et de leurs classifications anatomiques. L'IASLC a recueilli et publié de nombreuses données concernant la taille des tumeurs, l'implication des ganglions lymphatiques et le statut métastatique qui sont ensuite présentées à l'Union for International Cancer Control (UICC) et l'American Joint Committee on Cancer (AJCC) à des fins d'évaluation. Avant le Staging Project de l'IASLC, les données recueillies pour classifier les cancers du poumon provenaient d'un groupe de patients plus petit, presque exclusivement basés aux États-Unis. À propos de la WCLC : La WCLC est le plus important colloque au monde dédié au cancer du poumon et aux autres tumeurs thoraciques, réunissant plus de 6 000 chercheurs, médecins et spécialistes venus de plus de 100 pays. Son objectif est d'accroître la sensibilisation et de renforcer la collaboration et la compréhension du cancer du poumon, et d'aider les participants à mettre en œuvre les derniers développements partout dans le monde. Organisée sous le thème " Ensemble contre le cancer du poumon ", la conférence couvrira une vaste gamme de disciplines et dévoilera les résultats de plusieurs essais cliniques et études de recherche. Pour tout complément d'information, veuillez consulter le site http://wclc2016.iaslc.org/. L'Association internationale pour l'étude du cancer du poumon (IASLC) est la seule organisation mondiale qui se consacre à l'étude du cancer du poumon. Fondée en 1974, l'association compte parmi ses membres plus de 5 000 spécialistes du cancer du poumon issus de plus de 100 pays. Pour en savoir plus, rendez-vous à l'adresse www.iaslc.org.

Loading Guangdong Lung Cancer Institute collaborators
Loading Guangdong Lung Cancer Institute collaborators